Detalhe da pesquisa
1.
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Hepatology
; 56(3): 884-93, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22473713
2.
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Blood Adv
; 7(3): 414-421, 2023 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36383730
3.
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Vaccine
; 41(21): 3387-3398, 2023 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37105892
4.
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.
EBioMedicine
; 75: 103811, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35042081
5.
Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009.
Pediatr Infect Dis J
; 35(9): 1011-20, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27254037
6.
M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.
Vaccine
; 33(18): 2132-40, 2015 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25796337
7.
Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience.
Vaccine
; 30(48): 6918-26, 2012 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22959986